1 year follow-up for Cardiovascular Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Mayo Clinic in Rochester, Rochester, MNCardiovascular Disease+1 MoreNT-pro-BNP - DiagnosticTest
Eligibility
18 - 99
All Sexes
What conditions do you have?
Select

Study Summary

This trial is designed to improve cardiovascular care for adult cancer survivors. The goal is to gather data to plan and develop a nation-wide network of a screening program that can help provide cost-effective and long-term monitoring.

Eligible Conditions
  • Cardiovascular Disease
  • Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 5 Secondary · Reporting Duration: 1 year

1 year
Absolute change in AI-ECG probability for LVEF <50% from baseline to 1 year from anthracycline-based therapy
Absolute change in LVEF from baseline to 1 year from anthracycline-based therapy
Absolute change in NT-pro-BNP from baseline to 1 year from anthracycline-based therapy
Electrocardiogram
Correlation of change in LVEF and NT-pro-BNP from baseline to 1 year from anthracycline-based therapy
Year 1
Diagnostic performance of AI-ECG and NT-pro-BNP for left ventricular ejection fraction (LVEF) < 50%
Diagnostic performance of AI-ECG for left ventricular ejection fraction (LVEF) < 50%
Diagnostic performance of NT-pro-BNP for left ventricular ejection fraction (LVEF) < 50%

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

1 year follow-up
1 of 2
Prior to anthracycline-based therapy
1 of 2

Active Control

200 Total Participants · 2 Treatment Groups

Primary Treatment: 1 year follow-up · No Placebo Group · N/A

1 year follow-upActiveComparator Group · 3 Interventions: NT-pro-BNP, Electrocardiogram, Echocardiogram · Intervention Types: DiagnosticTest, DiagnosticTest, DiagnosticTest
Prior to anthracycline-based therapyActiveComparator Group · 3 Interventions: NT-pro-BNP, Electrocardiogram, Echocardiogram · Intervention Types: DiagnosticTest, DiagnosticTest, DiagnosticTest

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year

Who is running the clinical trial?

Mayo ClinicLead Sponsor
2,952 Previous Clinical Trials
3,447,585 Total Patients Enrolled
Miami Heart Research InstituteUNKNOWN
1 Previous Clinical Trials
450 Total Patients Enrolled
Joerg Herrmann, MDPrincipal InvestigatorMayo Clinic
2 Previous Clinical Trials
280 Total Patients Enrolled

Eligibility Criteria

Age 18 - 99 · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Is this research endeavor presently recruiting participants?

"At this time, the information hosted on clinicaltrials.gov reveals that recruitment for this trial is still taking place. The original posting was March 3rd 2022 and it has been reviewed as recently as November 15th of the same year." - Anonymous Online Contributor

Unverified Answer

What are the principal goals of this experiment?

"This clinical trial will be evaluating the diagnostic performance of NT-pro-BNP for left ventricular ejection fraction (LVEF) < 50%, over a 1 year post anthracycline therapy period. Secondary outcomes include assessing absolute change in LVEF and NT-pro BNP from baseline to one year after starting treatment, as well as determining any correlations between changes in these two variables." - Anonymous Online Contributor

Unverified Answer

How much support has this experiment gained from the public?

"Affirmative. Information hosted on clinicaltrials.gov corroborates that this medical trial, which was inaugurated on March 3rd 2022, is actively seeking participants. Around 200 individuals must be enrolled from a single research facility for the study to continue." - Anonymous Online Contributor

Unverified Answer

Are individuals under the age of 30 being accepted into this research initiative?

"The criteria for participation in this medical trial states that applicants must be 18 years or older, but cannot exceed the age of 99." - Anonymous Online Contributor

Unverified Answer

Are there any qualifications for participating in this trial?

"To qualify for this clinical trial, applicants must be between 18 and 99 years of age with a pre-existing cardiovascular condition. Additionally, they need to have been diagnosed breast cancer, lymphoma or sarcoma; plus they must either be currently undergoing or one year post completion of anthracycline therapy." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.